Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Adamis Pharmaceuticals Gets FDA Approval for Zimhi Injection Product

10/18/2021 | 05:55am EST

By Chris Wack

Adamis Pharmaceuticals Corp. said the U.S. Food and Drug Administration has approved its Zimhi naloxone HCL injection 5 mg/0.5 mL product.

Adamis said Zimhi is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose.

Naloxone is an opioid antagonist and is generally considered the drug of choice for immediate administration for opioid overdose. It works by blocking or reversing the effects of the opioid, including extreme drowsiness, slowed breathing, or loss of consciousness, Adamis said.

The company said it is preparing for the full commercial launch of Zimhi in the first quarter of 2022.

Adamis shares were up 21% to $1.35 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

10-18-21 0755ET

All news about ADAMIS PHARMACEUTICALS CORPORATION
11/23ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
11/23Adamis Regains Nasdaq Listing Compliance by Filing Late Quarterly Reports; Stock Slides
MT
11/23Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
GL
11/23Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
GL
11/22ADAMIS PHARMACEUTICALS : Announces Third Quarter 2021 Financial Results and Provides Corpo..
PU
11/22Adamis Pharmaceuticals Reports Increased Nine-Month Revenues From Epinephrine Sales
MT
11/22ADAMIS PHARMACEUTICALS CORP : Results of Operations and Financial Condition (form 8-K)
AQ
11/22ADAMIS : Q3 Earnings Snapshot
AQ
11/22Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corp..
GL
11/22ADAMIS PHARMACEUTICALS CORP Management's Discussion and Analysis of Financial Conditio..
AQ
More news
Financials (USD)
Sales 2021 10,2 M - -
Net income 2021 -34,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,39x
Yield 2021 -
Capitalization 121 M 121 M -
Capi. / Sales 2021 11,9x
Capi. / Sales 2022 12,4x
Nbr of Employees 130
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 0,81 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dennis J. Carlo President, Chief Executive Officer & Director
David C. Benedicto Chief Financial & Accounting Officer
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION67.78%121
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049